Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the debt to assets ratio high or low?
The debt to assets ratio of 53.60% is 172% above its 5-year average of 19.72%, near the high end of its 5-year range (7.34%–53.60%).
As of the fiscal period ended Tuesday, June 30, 2026. 28.35% above its 12-month average of 41.76%.
Reported quarterly debt to assets ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 53.60%.
DEBT TO ASSETS RATIO
53.60%
DEBT TO ASSETS RATIO AVG TTM
41.76%
DEBT TO ASSETS RATIO AVG 3Y
26.48%
DEBT TO ASSETS RATIO AVG 5Y
19.72%
DEBT TO ASSETS RATIO AVG 10Y
N/A
DEBT TO ASSETS RATIO AVG 15Y
N/A
DEBT TO ASSETS RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
+28.35%
CURRENT VS 3Y AVG
+102.43%
CURRENT VS 5Y AVG
+171.82%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.11%
median of 526 covered companies
CURRENT VS SECTOR MEDIAN
+50946.71%
vs the sector median at left
Bolt Biotherapeutics, Inc.
Market Cap
$7.03M
Debt to Assets Ratio
53.60%
TTM Avg
41.76%
3Y Avg
26.48%
5Y Avg
19.72%
Market Cap
$6.78M
Debt to Assets Ratio
0.11%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$6.52M
Debt to Assets Ratio
0.07%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$6.85M
Debt to Assets Ratio
0.00%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$7.09M
Debt to Assets Ratio
0.05%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | DEBT TO ASSETS RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Bolt Biotherapeutics, Inc. (BOLT) | $7.03M | 53.60% | 41.76% | 26.48% | 19.72% |
| KALA BIO, Inc. (KALA)vs › | $6.65M | 0.00% | N/A | N/A | N/A |
| Aclarion, Inc. (ACON)vs › | $6.78M | 0.00% | N/A | N/A | N/A |
| Co-Diagnostics, Inc. (CODX)vs › | $6.78M | 0.11% | N/A | N/A | N/A |
| Ensysce Biosciences, Inc. (ENSC)vs › | $6.52M | 0.07% | N/A | N/A | N/A |
| Enveric Biosciences, Inc. (ENVB)vs › | $6.85M | 0.00% | N/A | N/A | N/A |
| Biomerica, Inc. (BMRA)vs › | $6.40M | 0.28% | N/A | N/A | N/A |
| Curanex Pharmaceuticals Inc Common Stock (CURX)vs › | $7.09M | 0.05% | N/A | N/A | N/A |
| Femasys Inc. (FEMY)vs › | $6.25M | 0.39% | N/A | N/A | N/A |
| Enlivex Therapeutics Ltd. (ENLV)vs › | $6.23M | 0.00% | N/A | N/A | N/A |
Debt/Assets
53.6%
Debt/Equity
1.71
Current Ratio
2.61
Interest Coverage
N/A
Formula: Debt/Assets = Total Debt / Total Assets × 100
Debt/Assets vs Debt/Equity:
Industry context matters: Capital-intensive industries (utilities, real estate) typically have higher Debt/Assets ratios than tech companies.
Debt/Assets ratio shows what percentage of a company's assets are financed by debt. Compare the current value with the historical chart and peer group to understand leverage over time.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | DEBT TO ASSETS RATIO |
|---|---|
| 2026-06-30 | 53.60% |
| 2026-03-31 | 46.45% |
| 2025-12-31 | 40.46% |
| 2025-09-30 | 36.26% |
| 2025-06-30 | 32.03% |
| 2025-03-31 | 28.78% |
| 2024-12-31 | 25.30% |
| 2024-09-30 | 16.63% |
| 2024-06-30 | 15.21% |
| 2024-03-31 | 13.69% |
| 2023-12-31 | 12.65% |
| 2023-09-30 | 11.89% |
| 2023-06-30 | 11.26% |
| 2023-03-31 | 10.70% |
| 2022-12-31 | 9.93% |
| 2022-09-30 | 9.47% |
| 2022-06-30 | 8.80% |
| 2022-03-31 | 8.27% |
| 2021-12-31 | 7.91% |
| 2021-09-30 | 7.47% |
| 2021-06-30 | 7.34% |
| 2021-03-31 | 3.29% |
| 2020-12-31 | 23.37% |
| 2020-09-30 | 17.84% |
| 2020-06-30 | 11.38% |
| 2019-12-31 | 21.02% |
